CA4P (fosbretabulin)
Cancer (Pediatric Melanoma)
Phase 1/2Active
Key Facts
About Oncotelic Therapeutics
Oncotelic Therapeutics is a clinical-stage biotech founded in 2014, advancing a pipeline centered on OT-101, a novel anti-TGF-β RNA therapeutic for cancers like diffuse intrinsic pontine glioma (DIPG) and viral infections including COVID-19. The company leverages a dual strategy of traditional drug development and a novel AI/DAO-driven platform (PDAOAI/Pet2DAO) to enhance research efficiency. With a focus on rare pediatric cancers and a partnership-driven, capital-efficient business model, Oncotelic aims to translate its RNA and small molecule candidates into treatments for significant unmet medical needs.
View full company profile